
PAVmed Announces Q3 2025 Financial Results and Updates

I'm PortAI, I can summarize articles.
PAVmed Inc. announced its Q3 2025 financial results, reporting a GAAP net loss of $6.3 million and cash reserves of $3.1 million. Key developments include Veris Health's commercial launch, a new licensing agreement with Duke University, and Lucid Diagnostics' $1.2 million revenue from EsoGuard tests. The company faces financial challenges, with a Hold rating and $0.50 price target on its stock. PAVmed operates in medical technology, focusing on innovative solutions through subsidiaries like Lucid Diagnostics and Veris Health.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

